Clinical Trials That Have Changed Obstetric Practice : The Chronic Hypertension and Pregnancy (CHAP) Trial
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved..
We describe the evolution of treatment recommendations for chronic hypertension (CHTN) in pregnancy, the CHTN and pregnancy (CHAP) trial, and its impact on obstetric practice. The US multicenter CHAP trial showed that antihypertensive treatment for mild CHTN in pregnancy [blood pressures (BP)<160/105 mm Hg] to goal<140/90 mm Hg, primarily with labetalol or nifedipine compared with no treatment unless BP were severe reduced the composite risk of superimposed severe preeclampsia, indicated preterm birth <35 weeks, placental abruption, and fetal/neonatal death. As a result of this trial, professional societies in the United States recommended treatment of patients with CHTN in pregnancy to BP goal<140/90 mm Hg.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Clinical obstetrics and gynecology - 67(2024), 2 vom: 01. Mai, Seite 411-417 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanusi, Ayodeji A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive Agents |
|---|
| Anmerkungen: |
Date Completed 30.04.2024 Date Revised 03.05.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/GRF.0000000000000857 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369556372 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369556372 | ||
| 003 | DE-627 | ||
| 005 | 20240503232400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/GRF.0000000000000857 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1396.xml |
| 035 | |a (DE-627)NLM369556372 | ||
| 035 | |a (NLM)38465909 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanusi, Ayodeji A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Trials That Have Changed Obstetric Practice |b The Chronic Hypertension and Pregnancy (CHAP) Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2024 | ||
| 500 | |a Date Revised 03.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a We describe the evolution of treatment recommendations for chronic hypertension (CHTN) in pregnancy, the CHTN and pregnancy (CHAP) trial, and its impact on obstetric practice. The US multicenter CHAP trial showed that antihypertensive treatment for mild CHTN in pregnancy [blood pressures (BP)<160/105 mm Hg] to goal<140/90 mm Hg, primarily with labetalol or nifedipine compared with no treatment unless BP were severe reduced the composite risk of superimposed severe preeclampsia, indicated preterm birth <35 weeks, placental abruption, and fetal/neonatal death. As a result of this trial, professional societies in the United States recommended treatment of patients with CHTN in pregnancy to BP goal<140/90 mm Hg | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Nifedipine |2 NLM | |
| 650 | 7 | |a I9ZF7L6G2L |2 NLM | |
| 650 | 7 | |a Labetalol |2 NLM | |
| 650 | 7 | |a R5H8897N95 |2 NLM | |
| 700 | 1 | |a Sinkey, Rachel G |e verfasserin |4 aut | |
| 700 | 1 | |a Tita, Alan T N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical obstetrics and gynecology |d 1958 |g 67(2024), 2 vom: 01. Mai, Seite 411-417 |w (DE-627)NLM000175544 |x 1532-5520 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:2 |g day:01 |g month:05 |g pages:411-417 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/GRF.0000000000000857 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 2 |b 01 |c 05 |h 411-417 | ||